Nuclear factor-κB inhibitors as sensitizers to anticancer drugs

Chikashi Nakanishi, Masakazu Toi

Research output: Contribution to journalReview article

633 Citations (Scopus)

Abstract

The cytotoxicity of chemotherapeutic agents is attributed to apoptosis. Acquired resistance to the effects of chemotherapy has emerged as a significant impediment to effective cancer therapy. One feature that cytotoxic treatments of cancer have in common is their activation of the transcription factor nuclear factor-κB (NF-κB), which regulates cell survival. NF-κB activation suppresses the apoptotic potential of chemotherapeutic agents and contributes to resistance. What evidence is there that inhibitors of NF-κB might promote apoptosis in cancer cells and can NF-κB inhibitors be used to overcome resistance to chemotherapeutic agents?

Original languageEnglish
Pages (from-to)297-309
Number of pages13
JournalNature Reviews Cancer
Volume5
Issue number4
DOIs
Publication statusPublished - 2005 Apr 1

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Nuclear factor-κB inhibitors as sensitizers to anticancer drugs'. Together they form a unique fingerprint.

  • Cite this